CR10733A - Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof - Google Patents

Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof

Info

Publication number: CR10733A
Authority: CR; Costa Rica
Prior art keywords: benzothiepin; substituted; novel; compounds; benzyl groups
Prior art date: 2006-11-14

Application number

CR10733A

Other languages

English (en)

Inventor

Wendelln Frick

Heiner Glombik

Stefan Theis

Hubert Heuer

Hans-Ludwig Schaefer

Werner Kramer

Original Assignee

Sanofi Aventis Deutchsland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-14

Filing date

2009-04-20

Publication date

2009-05-25

2009-04-20 Application filed by Sanofi Aventis Deutchsland Gmbh filed Critical Sanofi Aventis Deutchsland Gmbh

2009-05-25 Publication of CR10733A publication Critical patent/CR10733A/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C07H7/027—Keto-aldonic acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CR10733A 2006-11-14 2009-04-20 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof CR10733A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102006053635A DE102006053635B4 (de)	2006-11-14	2006-11-14	Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (1)

Publication Number	Publication Date
CR10733A true CR10733A (es)	2009-05-25

Family

ID=39092812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR10733A CR10733A (es)	2006-11-14	2009-04-20	Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof

Country Status (38)

Country	Link
US (1)	US7956085B2 (es)
EP (1)	EP2084172B1 (es)
JP (1)	JP5301453B2 (es)
KR (1)	KR101489168B1 (es)
CN (1)	CN101535326B (es)
AR (2)	AR063786A1 (es)
AT (1)	ATE492554T1 (es)
AU (1)	AU2007321496B2 (es)
BR (1)	BRPI0718813B8 (es)
CA (2)	CA2865332C (es)
CL (1)	CL2007003262A1 (es)
CO (1)	CO6190534A2 (es)
CR (1)	CR10733A (es)
CY (1)	CY1111166T1 (es)
DE (2)	DE102006053635B4 (es)
DK (1)	DK2084172T3 (es)
EC (1)	ECSP099327A (es)
ES (1)	ES2358371T3 (es)
GT (1)	GT200900125A (es)
HK (1)	HK1137762A1 (es)
HR (1)	HRP20110197T1 (es)
IL (1)	IL198718A (es)
MA (1)	MA30883B1 (es)
MX (1)	MX2009003958A (es)
MY (1)	MY148429A (es)
NI (1)	NI200900076A (es)
NO (2)	NO342236B1 (es)
NZ (1)	NZ576762A (es)
PE (1)	PE20081493A1 (es)
PL (1)	PL2084172T3 (es)
PT (1)	PT2084172E (es)
RU (1)	RU2456282C2 (es)
SI (1)	SI2084172T1 (es)
SV (1)	SV2009003216A (es)
TN (1)	TN2009000180A1 (es)
TW (1)	TWI414530B (es)
UY (1)	UY30709A1 (es)
WO (1)	WO2008058628A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8461312B2 (en) *	2008-05-02	2013-06-11	Sanofi	Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives
EP2367554A4 (en)	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES
WO2011150286A2 (en)	2010-05-26	2011-12-01	Satiogen Pharmaceuticals,Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
KR101898610B1 (ko)	2010-08-31	2018-09-14	서울대학교산학협력단	ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
BR112013010157B1 (pt)	2010-11-08	2020-02-04	Albireo Ab	iinibidores do ibat, seus usos, e composição e combinações farmacêuticas
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104023718B (zh) *	2011-10-28	2017-04-05	鲁美纳医药公司	用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
KR102051030B1 (ko) *	2011-10-28	2019-12-02	루메나 파마수티컬즈, 인코포레이티드	소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh)	2014-06-25	2017-05-10	Ea制药株式会社	固体制剂及其着色防止或着色减少方法
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
ES2874669T3 (es)	2016-02-09	2021-11-05	Albireo Ab	Formulación oral de colestiramina y uso de la misma
JP6954927B2 (ja)	2016-02-09	2021-10-27	アルビレオ・アクチボラグ	経口コレスチラミン製剤及びその使用
JP2020530448A (ja)	2017-08-09	2020-10-22	アルビレオ・アクチボラグ	コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CA3071182A1 (en)	2017-08-09	2019-02-14	Albireo Ab	Cholestyramine pellets, oral cholestyramine formulations and use thereof
ES2942443T3 (es)	2018-06-05	2023-06-01	Albireo Ab	Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
CN112262130A (zh)	2018-06-20	2021-01-22	阿尔比里奥公司	奥德昔巴特的结晶修饰物
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
CN112638944A (zh)	2018-08-23	2021-04-09	西进公司	抗tigit抗体
US10975045B2 (en)	2019-02-06	2021-04-13	Aibireo AB	Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en)	2019-02-06	2021-03-09	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
CA3129827A1 (en)	2019-02-12	2020-08-20	Mirum Pharmaceuticals, Inc.	Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
CN114786772B (zh)	2019-12-04	2024-04-09	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
PL4069360T3 (pl)	2019-12-04	2024-04-29	Albireo Ab	Związki benzotio(di)azepinowe i ich zastosowanie jako modulatory kwasów żółciowych
JP2023504644A (ja)	2019-12-04	2023-02-06	アルビレオ・アクチボラグ	ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4188541A1 (en)	2020-08-03	2023-06-07	Albireo AB	Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en)	2020-11-12	2023-06-08	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en)	2020-12-04	2023-06-22	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2023203248A1 (en)	2022-04-22	2023-10-26	Albireo Ab	Subcutaneous administration of an asbt inhibitor
WO2023237728A1 (en)	2022-06-09	2023-12-14	Albireo Ab	Treating hepatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5994391A (en) *	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE19825804C2 (de) *	1998-06-10	2000-08-24	Aventis Pharma Gmbh	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
CA2457976A1 (en) *	2001-08-22	2003-03-06	Aventis Pharma Deutschland Gmbh	Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
GB0121621D0 (en) *	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
JP2005518347A (ja)	2001-11-02	2005-06-23	ジー．ディー．サールエルエルシー	頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
DE102005033099A1 (de)	2005-07-15	2007-01-18	Sanofi-Aventis Deutschland Gmbh	Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung

2006
- 2006-11-14 DE DE102006053635A patent/DE102006053635B4/de not_active Expired - Fee Related
2007
- 2007-10-30 NZ NZ576762A patent/NZ576762A/en unknown
- 2007-10-30 KR KR1020097009914A patent/KR101489168B1/ko active IP Right Grant
- 2007-10-30 PL PL07819434T patent/PL2084172T3/pl unknown
- 2007-10-30 CA CA2865332A patent/CA2865332C/en active Active
- 2007-10-30 BR BRPI0718813A patent/BRPI0718813B8/pt active IP Right Grant
- 2007-10-30 AT AT07819434T patent/ATE492554T1/de active
- 2007-10-30 ES ES07819434T patent/ES2358371T3/es active Active
- 2007-10-30 EP EP07819434A patent/EP2084172B1/de active Active
- 2007-10-30 CA CA2669230A patent/CA2669230C/en active Active
- 2007-10-30 WO PCT/EP2007/009393 patent/WO2008058628A1/de active Application Filing
- 2007-10-30 AU AU2007321496A patent/AU2007321496B2/en active Active
- 2007-10-30 CN CN2007800424399A patent/CN101535326B/zh active Active
- 2007-10-30 RU RU2009122470/04A patent/RU2456282C2/ru active
- 2007-10-30 SI SI200730487T patent/SI2084172T1/sl unknown
- 2007-10-30 PT PT07819434T patent/PT2084172E/pt unknown
- 2007-10-30 MY MYPI20091688A patent/MY148429A/en unknown
- 2007-10-30 DK DK07819434.7T patent/DK2084172T3/da active
- 2007-10-30 NO NO20091893A patent/NO342236B1/no unknown
- 2007-10-30 DE DE502007006055T patent/DE502007006055D1/de active Active
- 2007-10-30 MX MX2009003958A patent/MX2009003958A/es active IP Right Grant
- 2007-10-30 JP JP2009536625A patent/JP5301453B2/ja active Active
- 2007-11-12 PE PE2007001553A patent/PE20081493A1/es not_active Application Discontinuation
- 2007-11-12 AR ARP070105027A patent/AR063786A1/es active IP Right Grant
- 2007-11-12 UY UY30709A patent/UY30709A1/es unknown
- 2007-11-12 TW TW096142599A patent/TWI414530B/zh active
- 2007-11-13 CL CL200703262A patent/CL2007003262A1/es unknown
2009
- 2009-04-03 SV SV2009003216A patent/SV2009003216A/es unknown
- 2009-04-20 CR CR10733A patent/CR10733A/es not_active Application Discontinuation
- 2009-05-04 NI NI200900076A patent/NI200900076A/es unknown
- 2009-05-06 CO CO09045559A patent/CO6190534A2/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000180A patent/TN2009000180A1/fr unknown
- 2009-05-12 MA MA31864A patent/MA30883B1/fr unknown
- 2009-05-12 IL IL198718A patent/IL198718A/en active IP Right Grant
- 2009-05-13 GT GT200900125A patent/GT200900125A/es unknown
- 2009-05-13 EC EC2009009327A patent/ECSP099327A/es unknown
- 2009-05-14 US US12/465,911 patent/US7956085B2/en active Active
2010
- 2010-03-08 HK HK10102412.4A patent/HK1137762A1/xx unknown
2011
- 2011-02-04 CY CY20111100133T patent/CY1111166T1/el unknown
- 2011-03-17 HR HR20110197T patent/HRP20110197T1/hr unknown
2017
- 2017-07-12 AR ARP170101938A patent/AR109033A2/es unknown
2018
- 2018-04-11 NO NO20180497A patent/NO344589B1/no unknown

Also Published As

Publication number	Publication date
ES2358371T3 (es)	2011-05-10
PT2084172E (pt)	2011-02-10
DE102006053635B4 (de)	2011-06-30
CN101535326B (zh)	2012-10-31
CA2865332C (en)	2016-03-29
JP5301453B2 (ja)	2013-09-25
DE502007006055D1 (de)	2011-02-03
PE20081493A1 (es)	2008-11-24
SI2084172T1 (sl)	2011-03-31
TN2009000180A1 (en)	2010-10-18
SV2009003216A (es)	2010-05-26
KR20090082396A (ko)	2009-07-30
PL2084172T3 (pl)	2011-06-30
NI200900076A (es)	2010-01-29
MA30883B1 (fr)	2009-11-02
TW200837072A (en)	2008-09-16
BRPI0718813B8 (pt)	2021-05-25
DE102006053635A1 (de)	2008-05-15
NO342236B1 (no)	2018-04-23
JP2010509379A (ja)	2010-03-25
ECSP099327A (es)	2009-06-30
NO20091893L (no)	2009-07-09
HK1137762A1 (en)	2010-08-06
NO344589B1 (no)	2020-02-03
KR101489168B1 (ko)	2015-02-03
CA2669230C (en)	2015-01-13
BRPI0718813B1 (pt)	2020-12-08
CA2669230A1 (en)	2008-05-22
CN101535326A (zh)	2009-09-16
WO2008058628A1 (de)	2008-05-22
EP2084172B1 (de)	2010-12-22
NO20180497A1 (no)	2009-07-09
CO6190534A2 (es)	2010-08-19
GT200900125A (es)	2011-06-23
US7956085B2 (en)	2011-06-07
CL2007003262A1 (es)	2008-05-30
UY30709A1 (es)	2008-07-03
MY148429A (en)	2013-04-30
EP2084172A1 (de)	2009-08-05
AU2007321496A1 (en)	2008-05-22
AR063786A1 (es)	2009-02-18
TWI414530B (zh)	2013-11-11
BRPI0718813A2 (pt)	2013-12-03
RU2456282C2 (ru)	2012-07-20
MX2009003958A (es)	2009-04-27
DK2084172T3 (da)	2011-04-04
AR109033A2 (es)	2018-10-24
IL198718A0 (en)	2010-02-17
RU2009122470A (ru)	2010-12-20
CA2865332A1 (en)	2008-05-22
NZ576762A (en)	2010-11-26
CY1111166T1 (el)	2015-06-11
IL198718A (en)	2012-12-31
ATE492554T1 (de)	2011-01-15
US20100035961A1 (en)	2010-02-11
HRP20110197T1 (hr)	2011-04-30
AU2007321496B2 (en)	2012-07-26

Legal Events

Date	Code	Title	Description
2014-04-24	FA	Abandonment or withdrawal (granting procedure)

Publication	Publication Date	Title
CR10733A (es)	2009-05-25	Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
CY2014042I1 (el)	2015-12-09	Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζολιου, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους
ATE481383T1 (de)	2010-10-15	3-aza-bicycloä3.1.0ühexanderivate
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
BRPI0810646A2 (pt)	2014-11-04	" compostos farmacêuticos ".
ATE484499T1 (de)	2010-10-15	Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
RU2398586C3 (ru)	2017-10-04	Фармацевтическая композиция
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
ATE469145T1 (de)	2010-06-15	4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
ATE460401T1 (de)	2010-03-15	1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ITMO20050343A1 (it)	2007-06-24	Supporto per medicazione
DE602008005634D1 (de)	2011-04-28	1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
DK1957073T3 (da)	2014-05-12	Lægemiddel
DK1910325T3 (da)	2011-01-24	Nye farmaceutisk forbindelser
ATE502024T1 (de)	2011-04-15	Diosmetin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE602006018590D1 (de)	2011-01-13	Heteroarylharnstoffderivate zur hemmung von chk1
MA29033B1 (fr)	2007-11-01	Composes organiques
ATE372992T1 (de)	2007-09-15	Indanyl-piperazinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
BRPI0819202A2 (pt)	2015-05-05	Derivado heterocíclico, e, composição farmacêutica
ATE462408T1 (de)	2010-04-15	Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
ATE388936T1 (de)	2008-03-15	9-chloro-15-deoxyprostaglandinderivate, verfahren zu ihrer herstellung und deren verwendung als medikamente
DE602006018617D1 (de)	2011-01-13	Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
ATE441643T1 (de)	2009-09-15	N-ä(4,5-diphenylpyrimidin-2- yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung
ATE466863T1 (de)	2010-05-15	Neue aminopyrrolo-ä1,2-aü-indol- und aminopyridazino-ä1,6-aü-indol-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen damit